Bin Gao, MD, PhD
Year elected: 2007
Current membership category: Active
NIH Nat Inst on Alcoholism and Alcohol Abuse
5625 Fishers Lane, Rm 2s-33
Bethesda, MD 20892
United States of America
Dr. Gao received his M.D. and Ph.D. from Wannan Medical College and Norman Bethune Medical University, China, respectively. Following postdoctoral training at the National Institutes of Health (NIH) and Medical College of Virginia, he served as a tenure track Assistant Professor at Medical College of Virginia from 1995 to 2000, where his research was supported by three NIH grants. In 2000, he accepted a tenure track position and Section Chief of Liver Biology at National Insitute on Alcohol Abuse and Alcoholism (NIAAA), NIH. Of exceptional note, he was granted NIH tenure through the Central Tenure Committee in 2005 – a year early before his tenure track appointment was completed. In recognition of his meritorious and outstanding contributions as a Physician-Scientist, in 2007, Dr. Gao was elected to the prestigious American Society for Clinical Investigation (ASCI) on his initial nomination. In the same year, he was also selected by NIH Director to become member of the Senior Biomedical Research Service (SBRS). In 2009, Dr. Gao was promoted to the Laboratory Chief of Liver Diseases at NIAAA. He also received 2020 NIAAA Scientific Achievement Award.
Since rejoining NIAAA in 2000, Dr. Gao has established a highly productive liver research laboratory at NIH. Dr. Gao’s group is studying basic liver immunology and liver biology, and using the knowledge gained through these studies to investigate the pathogenesis of fatty liver diseases and their associated liver cancer and metabolic syndrome, and to explore novel therapeutic targets for these maladies. Over the past several years, Dr. Gao’s group has extensively investigated various types of inflammatory cells and the cytokines produced by these cells that control liver injury and cancer, and explored their therapeutic potential for liver diseases. Particularly, Dr. Gao first discovered interleukin-22 as a key survival factor for hepatocytes in 2004, and subsequently characterized interleukin-22 biology in the liver. These studies led to the ongoing interleukin-22 clinical trials for the treatment of acute liver failure such as alcoholic hepatitis. Recently, Dr. Gao’s lab has established several mouse models including chronic-plus-binge ethanol feeding, high-fat diet-plus-binge ethanol feeding, acute-on-chronic liver failure, neutrophil-driven nonalcoholic steatohepatitis, and Cre recombinase inducible human CD59 transgenic mouse model of cell ablation. By using these models, many novel mechanisms underlying liver injury and regeneration have been identified.
Dr. Gao has published over 200 papers, including 160 peer-reviewed original articles in highly prestigious journals including the Journal of Clinical Investigation, JCI Insight, Gastroenterology, Gut, Hepatolology etc. Dr. Gao has been invited to write Editorials and Reviews for many highly prestigious journals including Journal of Clinical Investigation, Nature Medicine, Gastroenterology, Hepatology, Gut etc. Dr. Gao was also often invited to organize, chair, and speak in many major national and international conferences. He is currently serving on the Editorial board for Gastroenterology, Gut, Hepatology, Journal of Hepatology etc., and Associate Editor-in-Chief for Cellular & Molecular Immunology.